Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Gerds on the Development of Anemia in Low-Risk Myelofibrosis

May 7th 2025

Aaron Gerds, MD, details the prevalence of anemia in patients with low- to intermediate-1–risk myelofibrosis.

FDA Grants Fast Track Designation to Givinostat for Polycythemia Vera

May 6th 2025

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis

April 30th 2025

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.

Dr Vachhani on the Potential Disease-Modifying Benefits of Navtemadlin in Myelofibrosis

April 28th 2025

Pankit Vachhani, MD, discusses the ongoing investigation of navtemadlin either alone or as an add-on to ruxolitinib for patients with myelofibrosis.

Dr Sekeres on Next Steps for Evaluating the Association Between Smoking and MDS

April 25th 2025

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Dr Harrison on Factors Influencing Patient Prognosis and Treatment Selection in Myelofibrosis

April 22nd 2025

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Dr Rampal on the Benefits and Limitations of JAK Inhibitors in Myelofibrosis

April 21st 2025

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis

April 18th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis

April 18th 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

April 15th 2025

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Dr Hernández-Boluda on the Rationale for Using Machine Learning to Predict Post-HCT Outcomes in Myelofibrosis

April 14th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Dr Rampal on Personalizing Treatment Strategies for Patients With Myelofibrosis

April 10th 2025

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Sekeres on the Importance of Counseling Patients With MDS on the Benefits of Smoking Cessation

April 7th 2025

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

Oral Decitabine/Cedazuridine Is an Effective, At-Home Treatment Option for MDS and CMML

April 5th 2025

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

April 3rd 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

March 31st 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.